Kevin Boyle, Sr. Biography and Net Worth

CEO of ZIOPHARM Oncology

Presently, Kevin S. Boyle holds the position of Chief Executive Officer & Director at ZIOPHARM Oncology, Inc. Mr. Boyle is also on the board of Texas Hearing Institute.

In his past career he was Chief Financial Officer of Sigma Cubed, Inc., Chief Financial Officer for Floworks International LLC, Chief Executive Officer & Director at Kuur Therapeutics Ltd, Chief Financial Officer for RecoverCare LLC, Director-Planning & Development at Great Lakes Transportation LLC, Treasurer for Seabulk International, Inc. and Treasurer & Vice President for American Commercial Lines, Inc.

Kevin S. Boyle received a graduate degree from the University of Pennsylvania and an undergraduate degree from Carnegie Mellon University.

How do I contact Kevin S. Boyle, Sr.?: The corporate mailing address for Mr. Boyle, Sr. and other ZIOPHARM Oncology executives is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. ZIOPHARM Oncology can also be reached via phone at (617) 259-1970 and via email at [email protected]. Learn More on Kevin S. Boyle, Sr.'s contact information.
Has Kevin S. Boyle, Sr. been buying or selling shares of ZIOPHARM Oncology?: Kevin S. Boyle, Sr. has not been actively trading shares of ZIOPHARM Oncology during the last ninety days. Learn More on Kevin S. Boyle, Sr.'s trading history.
Who are ZIOPHARM Oncology's active insiders?: ZIOPHARM Oncology's insider roster includes Kevin Boyle, Sr. (CEO), Eleanor de Groot (EVP), Heidi Hagen (Director), and Jaime Vieser (Director). Learn More on ZIOPHARM Oncology's active insiders.

Kevin S. Boyle, Sr. Insider Trading History at ZIOPHARM Oncology

Kevin S. Boyle, Sr. Buying and Selling Activity at ZIOPHARM Oncology

ZIOPHARM Oncology Company Overview

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Today's Range

Now: N/A

50 Day Range

MA: $1.08

$0.82

$1.39

2 Week Range

Now: N/A

Volume

2,127,500 shs

Average Volume

2,008,312 shs

Market Capitalization

$187.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Is NVDA a sell? Buy this stock instead before Dec 3

From Chaikin Analytics | Ad

After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is making headlines for last week's new earnings report – which revealed the AI juggernaut nearly doubled their profits in the last year alone.

A 50-year Wall Street veteran gives his answer Nvidia, right here...